Decitabine: a promising epi-immunotherapeutic agent in solid tumors.
Decitabine: a promising epi-immunotherapeutic agent in solid tumors.
复制标题
DOI：
10.1586/1744666x.2015.1002397
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Han Weidong
中科院分区：
文献类型：
--
作者：
Li Xiang;Mei Qian;Nie Jing;Fu Xiaobing;Han Weidong
The incidence of malignancies is increasing worldwide. Despite early detection, surgical resection, chemotherapy and radiotherapy, numerous patients continue to die from metastasis or recurrence. The immune system has the capacity to eradicate cancer cells; however, many tumors, especially solid tumors, present considerable challenges that render immune cells ineffectual, making cancer cells almost 'invisible' to the immune system. Compelling evidence has demonstrated that DNA methylation is involved in tumor development and progression, leading to the impaired immunogenicity and immune recognition of cancer cells. The hypomethylating agent decitabine has been shown to have therapeutic effects in malignancies and exhibits an effective immune efficacy in eliminating cancer cells. Based on the hypomethylating and immune remodeling effects of decitabine, we propose in this review that decitabine can be considered an epi-immunotherapeutic agent. We summarize the results of recent preclinical studies and clinical trials for decitabine and discuss the connections among its hypomethylating effect, immune-activated mechanisms and clinical activity in solid tumors, keeping in mind the goal of optimizing dosing schedules.
